Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.69 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 4/20 | 0.58 |
| ▸ | BCHE | P06276 | 3/20 | 0.58 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.53 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.53 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13143814 | 1.00 | FDPS (0.69) | FDPSMAOBACHEBCHETXNRD1 | |
| SCHEMBL583609 | 1.00 | FDPS (0.69) | FDPSMAOBACHEBCHETXNRD1 | |
| SCHEMBL16459818 | 0.89 | FDPS (0.52) | FDPSMAOBTXNRD1TXNRD3TXNRD2 | |
| SCHEMBL16459820 | 0.89 | FDPS (0.52) | FDPSMAOBTXNRD1TXNRD3TXNRD2 | |
| SCHEMBL16460041 | 0.88 | NFE2L2 (0.64) | FDPSMAOBTXNRD1TXNRD3TXNRD2 | |
| SCHEMBL582919 | 0.88 | KDM4E (0.64) | ACHETXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL582918 | 0.88 | KDM4E (0.64) | ACHETXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL16460040 | 0.88 | NFE2L2 (0.64) | FDPSMAOBTXNRD1TXNRD3TXNRD2 | |
| SCHEMBL20144419 | 0.82 | MAOB (0.68) | MAOBTXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL8046251 | 0.82 | FDPS (0.84) | FDPSMAOBACHEBCHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350033-B2 | 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2013-01-08 | — | — | US | disclosed |
| US-8350033-B2 | 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2013-01-08 | — | — | US | disclosed |
| EP-2213666-B1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | LI JIAMING (CN) | 2012-02-15 | — | — | EP | disclosed |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2010-09-09 | — | — | US | disclosed |
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2010-09-09 | — | — | US | disclosed |
| EP-2213666-A1 | LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION | Li, Jiaming (CN) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228029-A1 | Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application | AHR, CYP3A5, CYP3A43 | FDPS 2293/4885MAOB 1402/4885ACHE 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.